Hormones and Cardiovascular Disease
Director: Pierre-Yves Scarabin

Hormones and Cardiovascular Disease
Director: Pierre-Yves Scarabin

Hormones and Cardiovascular Disease
Director: Pierre-Yves Scarabin

 

Background

 

Recent data suggested that transdermic estrogens have no or little effect on the venous thrombotic risk among menopausal women. Whether transdermal estrogens are safe among women at high risk for venous thromboembolism is unknown. The impact of the progestins is also unknown.

 

Study design

 

The MEVE study (Menopause Estrogen Venous Events) study is a cohort study among outpatients from the Hotel-Dieu Hospital in Paris. This study aims to assess the safety of transdermal estrogens among women with personal history of venous thrombosis. Population study consists of postmenopausal women aged 45 to 70 years with a first documented episode of venous thrombosisBetween 2000 and 2008, we included retrospectively about 1.000 consecutive outpatient cases. Baseline data include detailed information on the first episode of venous thrombosis, the presence of prothrombotic mutations, the time of discontinuation of vitamin K antogonist therapy, reproductive factors and hormonal treatment use. Women will be asked to return a mailed questionnaire, including information on recurrent venous thrombosis, use and type of hormonal treatment. The end point of the study will be recurrent deep vein thrombosis or recurrent pulmonary embolism. Recurrent clinical events will have to be confirmed by imaging procedure. About 200 recurrent thrombotic events are expected.  

 

Funding

The MEVE study is supported by Inserm and by a grant from Pierre-Fabre Santé.  

© Esther 2019